Suppr超能文献

米兰标准范围内射频消融治疗肝细胞癌的时间趋势和长期结果。

Temporal trends and long-term outcomes of radiofrequency ablation for hepatocellular carcinoma within the Milan criteria.

机构信息

Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, 130 Dongdeok-ro, Jung-gu, Daegu, 41944, Republic of Korea.

Department of Radiology, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Republic of Korea.

出版信息

Sci Rep. 2024 Aug 27;14(1):19815. doi: 10.1038/s41598-024-70494-4.

Abstract

No study has analysed the temporal trends of the long-term results and clinical characteristics of patients with hepatocellular carcinoma (HCC) treated using radiofrequency ablation (RFA). Therefore, we examined temporal trends of characteristics of patients and treatment-naïve HCCs within the Milan criteria treated by RFA over 20 years. We retrospectively analysed 1099 patients with HCC within the Milan criteria treated with percutaneous RFA from January 2000 to December 2019. The overall survival (OS), recurrence-free survival (RFS), and factors affecting survival and local tumor progression were analysed using the Kaplan‒Meier method and Cox proportional hazards model. A trend test was performed to analyse the changing trends in participants and treatment outcomes. The overall and RFS of patients improved during the later period. In addition, viral hepatitis-related HCC incidence decreased, whereas that of alcohol- or non-alcoholic fatty liver disease-related HCC increased from the earlier to the later period (P for trend < 0.001). HBV antiviral therapy was increased and improved OS and RFS in patients treated using RFA. The outcomes after RFA over a 20-year period improved due to changes over time in target tumors and patients. The results could be useful for selecting patients who will benefit from RFA.

摘要

尚无研究分析接受射频消融 (RFA) 治疗的肝细胞癌 (HCC) 患者的长期结果和临床特征的时间趋势。因此,我们研究了 20 多年来接受 RFA 治疗的符合米兰标准的 HCC 患者和治疗初治 HCC 的特征的时间趋势。我们回顾性分析了 2000 年 1 月至 2019 年 12 月期间接受经皮 RFA 治疗的符合米兰标准的 1099 例 HCC 患者。使用 Kaplan-Meier 方法和 Cox 比例风险模型分析总生存率 (OS)、无复发生存率 (RFS) 以及影响生存和局部肿瘤进展的因素。进行趋势检验以分析参与者和治疗结果的变化趋势。患者的整体和 RFS 在后期有所改善。此外,病毒性肝炎相关 HCC 的发病率下降,而酒精或非酒精性脂肪性肝病相关 HCC 的发病率从早期到后期增加(趋势检验 P < 0.001)。HBV 抗病毒治疗的增加改善了接受 RFA 治疗的患者的 OS 和 RFS。由于目标肿瘤和患者随时间的变化,20 年来 RFA 的结果得到了改善。这些结果对于选择将从 RFA 中受益的患者可能有用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8007/11349757/baecd0166008/41598_2024_70494_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验